In today’s briefing:
- China Internet Weekly (23Jan2023): Tencent, Meituan, NetEase, Activision Blizzard
- Sciclone Pharmaceuticals (6600.HK) – The Business, the Outlook and the Challenges
China Internet Weekly (23Jan2023): Tencent, Meituan, NetEase, Activision Blizzard
- The authorities approved three of Tencent’s games in January 2023 after five in December 2022.
- Tencent closed its XR business and terminated a property rental contract.
- NetEase refused to extend service for Activision Blizzard for additional six months.
Sciclone Pharmaceuticals (6600.HK) – The Business, the Outlook and the Challenges
- Zadaxin has been the biggest performance driver of SciClone, but it would face the risk of losing market share and increased pricing pressures after generic drugs were included in VBP.
- SciClone is primarily a pharmaceutical development/sales company, rather than a research-based innovative drug company.The increasingly low cost performance of in-licensed products has made the capital “reconsider” and be more rational.
- SciClone is a good stock for short-term trade, especially by taking advantage of the positive momentum after it reaches licensing deals/launches new products, but we’re concerned about its long-term prospects.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars